Exact Mass: 505.3614486

Exact Mass Matches: 505.3614486

Found 42 metabolites which its exact mass value is equals to given mass value 505.3614486, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

LysoPC(P-18:1(9Z)/0:0)

(2-{[(2R)-2-hydroxy-3-[(1Z,9Z)-octadeca-1,9-dien-1-yloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H52NO6P (505.35320620000005)


LysoPC(P-18:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(P-18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. LysoPC(P-18:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(P-18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

   
   
   
   

PC(O-18:2/0:0)[U]

3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (Z,Z)-(1)-

C26H52NO6P (505.35320620000005)


   

LPC(p18:1)

1-(1Z,9Z-octadecadienyl)-sn-glycero-3-phosphocholine

C26H52NO6P (505.35320620000005)


   

C-8 Ceramide-1-phosphate

N-octanoylsphingosine-1-phosphate

C26H52NO6P (505.35320620000005)


   

LPC O-18:2

1-(1Z,9Z-octadecadienyl)-sn-glycero-3-phosphocholine

C26H52NO6P (505.35320620000005)


   

C8 CerP

N-(octanoyl)-sphing-4-enine-1-phosphate

C26H52NO6P (505.35320620000005)


   

N-octanoylsphingosine 1-phosphate

N-octanoylsphingosine 1-phosphate

C26H52NO6P (505.35320620000005)


An N-acylsphingosine 1-phosphate in which the N-acyl group is specified as octanoyl.

   

[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H52NO6P (505.35320620000005)


   
   
   
   
   
   
   
   
   
   
   

2-aminoethyl [3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-hydroxypropyl] hydrogen phosphate

2-aminoethyl [3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-hydroxypropyl] hydrogen phosphate

C26H52NO6P (505.35320620000005)


   

HexCer 10:0;2O/10:0

HexCer 10:0;2O/10:0

C26H51NO8 (505.3614486)


   

N-(dodecanoyl)-4E-tetradecasphingenine-1-phosphate

N-(dodecanoyl)-4E-tetradecasphingenine-1-phosphate

C26H52NO6P (505.35320620000005)


   

N-(decanoyl)-4E-hexadecasphingenine-1-phosphate

N-(decanoyl)-4E-hexadecasphingenine-1-phosphate

C26H52NO6P (505.35320620000005)


   

cis-5-(6-(1,3-Dioxan-2-YL)hexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

cis-5-(6-(1,3-Dioxan-2-YL)hexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

C33H47NO3 (505.3555752)


   

1-[(1Z,9Z)-octadecadienyl]-sn-glycero-3-phosphocholine

1-[(1Z,9Z)-octadecadienyl]-sn-glycero-3-phosphocholine

C26H52NO6P (505.35320620000005)


A 1-(Z)-alk-1-enyl-sn-glycero-3-phosphocholine in which the alkenyl group is (1Z,9Z)-octadecadienyl.

   

lysophosphatidylcholine P-18:1/0:0

lysophosphatidylcholine P-18:1/0:0

C26H52NO6P (505.35320620000005)


A lysophosphatidylcholine P-18:1 in which the alkenyl group is located at position 1.

   
   
   
   
   
   
   

13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide

13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide

C33H47NO3 (505.3555752)


   

(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C33H47NO3 (505.3555752)


   

(3r)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3r)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3555752)


   

(3s)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3s)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3555752)


   

(3r)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3r)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3555752)


   

(8e,10e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(8e,10e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C33H47NO3 (505.3555752)


   

(3s)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3s)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3555752)


   

3-{[3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

3-{[3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3555752)